NKMax and Merck KGaA, Darmstadt, Germany Expand Clinical Collaboration to Include Phase I/IIa Trial Investigating the Combination of SNK01 with ERBITUX® (cetuximab) in Metastatic NSCLC
SEOUL, South Korea, April 13, 2021 (GLOBE NEWSWIRE) — NKMax, a biotechnology company harnessing the power of the body’s immune…